🇺🇸·6h agoIndustry
Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
Publisher
M
Merck & Co. (MSD) News
USA
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Merck & Co. (MSD) News
- Region
- USA
- Scope
- Industry
- Published
- September 21, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on merck.com
Leave the platform to read the original full article on the publisher site.
Source: Merck & Co. (MSD) News
Scope: Industry
Related coverage
More related coverage
AbbVie News/5h ago
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
Aspen Pharmacare/9h ago
Aspen achieves Top 10 ranking for Integrated Reporting Excellence
Tiziana Life Sciences/6h ago
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
pharma.be Belgium/9h ago